Latest Aripiprazole Stories
Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.
WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients.
Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Report from Decision Resources Patient-Flow Forecasts Need to Take Into Account Shifts in Seroquel XR's Use by Line of Therapy Over the Next Two Years WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that AstraZeneca Seroquel's...
Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression, According to a New Report from Decision Resources WALTHAM, Mass., April 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar...
Altmeyer brings extensive experience in neuroscience and oncology to OAPI, further strengthening the company's growth in these therapeutic categories ROCKVILLE, Md. and PRINCETON, N.J., Feb. 12 /PRNewswire/ -- Otsuka America Pharmaceutical, Inc.
WALTHAM, Mass., Dec.
Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, has initiated its first Phase IIa clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine.
NEW YORK (Reuters Health) - The anti-psychotic drug Abilify (aripiprazole) appears to be a safe and effective treatment for patients with borderline personality disorder, often leading to improvements in health-related quality of life and interpersonal problems, a study suggests.
By Karla Gale NEW YORK (Reuters Health) - The atypical antipsychotic drug Abilify (aripiprazole) appears to enhance the response to antidepressants in patients with treatment-resistant major depression, research suggests.
Some newer antipsychotic medications may be associated with a small increased risk of death when used to treat elderly dementia patients, psychiatrists at Johns Hopkins warn.